{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:24:20Z","timestamp":1794029060590,"version":"4.8.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In the phase 3 AGILE study, after a 12.4-month median follow-up, ivosidenib, a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor, combined with azacitidine significantly improved event-free survival, overall survival (OS), and complete remission rates compared with placebo-azacitidine in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML), who were unfit for intensive chemotherapy. This post hoc analysis reports long-term follow-up results from AGILE after a median follow-up of 28.6 months. Overall, 148 patients were randomized to receive ivosidenib-azacitidine (n = 73) or placebo-azacitidine (n = 75). Median OS was significantly longer with ivosidenib (29.3 months; 95% confidence interval [CI], 13.2 to not reached) than with placebo (7.9 months; 95% CI, 4.1-11.3; hazard ratio, 0.42 [95% CI, 0.27-0.65]; P &amp;lt; .0001). Hematologic recovery was faster, more durable, and conversion to transfusion independence (53.8% vs 17.1%; P = .0004) was more common with ivosidenib than with placebo. Of 33 ivosidenib-treated patients evaluable for molecular measurable residual disease (MRD), 10 converted to MRD negativity. Although OS did not differ significantly between MRD-negative and MRD-positive responders at the 0.1% variant allele frequency (VAF) threshold, MRD-negative patients had numerically longer survival. MRD status appeared more predictive of long-term OS when an exploratory 1% VAF threshold was applied. MRD response was not associated with IDH1 variant, VAF, inferred clonality, or number of baseline comutations. The previously reported safety profile was maintained. These long-term efficacy and safety results confirm the benefit of ivosidenib-azacitidine in this challenging-to-treat population and support its use as a standard of care with the longest reported survival benefit for intensive chemotherapy\u2013ineligible patients with IDH1-mutated AML. This trial was registered at www.ClinicalTrials.gov as #NCT03173248.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016399","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:59:02Z","timestamp":1753390742000},"page":"5177-5189","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed\n                    <i>IDH1<\/i>\n                    -mutated AML"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hospital Universitari i Polit\u00e8cnic La Fe, Val\u00e8ncia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan M.","family":"Marchione","sequence":"additional","affiliation":[{"name":"2Servier BioInnovation, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"Recher","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Universit\u00e9 de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, CHU de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital Universitario Germans Trias i Pujol-ICO Badalona, Josep Carreras Research Institute, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-1546","authenticated-orcid":false,"given":"Ewa","family":"Zarzycka","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"7Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Riva","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Oncology and Molecular Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-6029","authenticated-orcid":false,"given":"Rodrigo T.","family":"Calado","sequence":"additional","affiliation":[{"name":"9Department of Medical Imaging, Hematology and Oncology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Oncology, Department of Internal Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-2121","authenticated-orcid":false,"given":"Adriana E.","family":"Tron","sequence":"additional","affiliation":[{"name":"2Servier BioInnovation, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0002-5350","authenticated-orcid":false,"given":"Jianan","family":"Hui","sequence":"additional","affiliation":[{"name":"2Servier BioInnovation, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9540-8870","authenticated-orcid":false,"given":"Diego A.","family":"Gianolio","sequence":"additional","affiliation":[{"name":"2Servier BioInnovation, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-4198","authenticated-orcid":false,"given":"Sung","family":"Choe","sequence":"additional","affiliation":[{"name":"2Servier BioInnovation, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapti","family":"Patel","sequence":"additional","affiliation":[{"name":"2Servier BioInnovation, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"St\u00e9phane","family":"De Botton","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Institut Gustave Roussy, Facult\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"13Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"14Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"12","key":"2025102810015108200_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025102810015108200_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"2025102810015108200_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"2025102810015108200_bib4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"issue":"22","key":"2025102810015108200_bib5","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2025102810015108200_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2025102810015108200_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025102810015108200_bib8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2023-173033","article-title":"A comparison of acute myeloid leukemia (AML) regimens: hypomethylating agents combined with ivosidenib or venetoclax in newly diagnosed patients with IDH1 mutations: a real-world evidence study [abstract]","volume":"142","author":"Smith","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025102810015108200_bib9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"20","key":"2025102810015108200_bib10","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2025102810015108200_bib11","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"2025102810015108200_bib12","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","article-title":"Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study","volume":"6","author":"Middeke","year":"2022","journal-title":"Blood Adv"},{"issue":"7516","key":"2025102810015108200_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"issue":"6","key":"2025102810015108200_bib14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3390\/biomedicines10061359","article-title":"2-Hydroxyglutarate in acute myeloid leukemia: a journey from pathogenesis to therapies","volume":"10","author":"Raimondi","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"2025102810015108200_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"2025102810015108200_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front Oncol"},{"issue":"21","key":"2025102810015108200_bib17","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1158\/1078-0432.CCR-17-1423","article-title":"Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature","volume":"23","author":"Craddock","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025102810015108200_bib18","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3324\/haematol.2020.263806","article-title":"Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project","volume":"106","author":"Sargas","year":"2021","journal-title":"Haematologica"},{"key":"2025102810015108200_bib19","unstructured":"TIBSOVO (ivosidenib tablets), for oral use. Highlights of prescribing information. Servier Pharmaceuticals; 2023. Accessed 3 December 2024. https:\/\/www.tibsovopro.com\/pdf\/prescribinginformation.pdf."},{"key":"2025102810015108200_bib20","unstructured":"Tibsovo (ivosidenib). Summary of product characteristics. Les Laboratoires Pharmaceuticals; 2023. Accessed 3 December 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tibsovo-epar-product-information_en.pdf."},{"issue":"16","key":"2025102810015108200_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025102810015108200_bib22","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood-2019-122590","article-title":"High rate of IDH1 mutation clearance and measurable residual disease negativity in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib (AG-120) and azacitidine","volume":"134","author":"Daigle","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025102810015108200_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/blood-2022-159473","article-title":"Molecular characterization of clinical response and relapse in patients with IDH1m ND-AML treated with Ivo+AZA in the AGILE study","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2025102810015108200_bib24","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025102810015108200_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"8","key":"2025102810015108200_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025102810015108200_bib27","first-page":"2088","article-title":"Azacitidine and venetoclax in AML. Reply","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2025102810015108200_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"2025102810015108200_bib29","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025102810015108200_bib30","doi-asserted-by":"crossref","first-page":"e0224097","DOI":"10.1371\/journal.pone.0224097","article-title":"Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing","volume":"14","author":"Balagopal","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"2025102810015108200_bib31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2025102810015108200_bib32","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3390\/cancers15082267","article-title":"Incidence and risk factors for development of cardiac toxicity in adult patients with newly diagnosed acute myeloid leukemia","volume":"15","author":"Boluda","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"13","key":"2025102810015108200_bib33","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2025102810015108200_bib34","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"21","key":"2025102810015108200_bib35","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"2025102810015108200_bib36","unstructured":"An open-label phase 3b study of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy. ClinicalTrials.gov identifier: NCT05907057. Updated 11 April 2025. Accessed 1 January 2025. https:\/\/clinicaltrials.gov\/study\/NCT05907057?term=NCT05907057&rank=1."},{"key":"2025102810015108200_bib37","unstructured":"A study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy, followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myedysplastic syndrome EB2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy (HOVON150AML). ClinicalTrials.gov identifier: NCT03839771. Updated 2 October 2024. Accessed 1 January 2025. https:\/\/clinicaltrials.gov\/study\/NCT03839771."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5177\/2416690\/blooda_adv-2025-016399-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5177\/2416690\/blooda_adv-2025-016399-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:02:05Z","timestamp":1761660125000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5177\/546354\/Long-term-results-from-the-AGILE-study-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":37,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016399","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,15]]}}}